Search results
Alzheimer's drug from Eisai and Biogen rejected in Europe
Reuters via Yahoo Canada News· 5 days agos disease, saying the risk of serious brain swelling did not outweigh its small impact on slowing...
Lilly Loses $120 Billion in Value as Rival Obesity Drugs Impress
Bloomberg· 6 days agoHave a confidential tip for our reporters? Eli Lilly & Co. is down more than $120 billion in market...
Wall Street is still jittery on GLP-1s
Yahoo Finance· 2 days agoWall Street has taken medical devices, as well as other sectors, on a roller-coaster ride in the past year in anticipation of an outsized impact from...
Swiss pharma firm Lonza's profit falls less than feared, shares rise
Reuters via Yahoo Finance Canada· 6 days ago(Reuters) -Swiss contract drug manufacturer Lonza reported a smaller-than-expected decline in...
Alzheimer's drug from Eisai and Biogen rejected in Europe
Nikkei Asian Review· 5 days agoThe decision is a blow to the companies as the drug faces slow take-up in the U.S. and underscores...
Is CVS Health Corporation (CVS) the Best Health Insurance Stock to Buy Now?
Insider Monkey via Yahoo Finance Canada· 4 days agoWe recently compiled a list of the 10 Best Health Insurance Stocks to Buy. In this article, we are...
European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval
Associated Press Finance via Yahoo Finance Canada· 5 days agoThe European Medicines Agency committee said concerns about the drug’s potential side effects...
Roche to fast-track weight loss drugs to compete with rivals, FT reports
Reuters via Yahoo Finance Canada· 2 days agoRoche is among a growing number of would-be rivals to Novo and Eli Lilly, whose weight-loss...
Ozempic predecessor suggests potential for GLP-1 drugs in Alzheimer’s in early trial
CNN via Yahoo Canada News· 1 day agoA small clinical trial suggests that drugs like Ozempic could potentially be used not just for...
Patients push back against Novo Nordisk move to scrap an insulin product
Reuters via Yahoo Finance Canada· 1 day agoNovo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has...